This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
News|Articles|January 26, 2016
European Pharmacopoeia Publishes Chemometrics Chapter
Author(s)Pharmaceutical Technology Editors
The European Directorate for the Quality of Medicines & Healthcare announces the publication of a chemometric methods chapter in the European Pharmacopoeia.
The European Directorate for the Quality of Medicines & Healthcare (EDQM) announced on Jan. 25, 2016 the publication of a new chapter in the European Pharmacopoeia Supplement 8.7. “Chemometric methods applied to analytical data” (5.21) introduces the use of chemometric techniques for processing analytical data sets.
The chapter provides good chemometric practice guidelines and requirements and offers a selection of established, most used chemometric methods. Included in chapter 5.21 are an introduction to chemometric methods; good chemometric practice including figures of merit, implementation steps, data considerations, and maintenance; an assessment and validation of chemometric methods; a description of important chemometric techniques; and a glossary.
The agency defines chemometrics, in a press release, “as the chemical discipline that uses mathematical and statistical methods to design optimal measurement procedures and to provide maximum chemical information by analyzing chemical data. It mainly consists of multivariate modeling techniques that result in empirical mathematical models used for the prediction of properties. It helps to structure data sets and to recognize hidden relationships within the system.” EDQM hopes the chapter will encourage the use of chemometric methods for evaluating data generated by near-infrared, Raman, mass, and other spectroscopic methods, as well as data from liquid chromatography–mass spectrometry.
Source:
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.